Progeny 3 Inc’s Vaxcyte PCVX Stock Holding History

Progeny 3 Inc’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,300	Closed	-$1.35M	–	33
2026 Q1	$1.35M	Hold	23,300	–	–	0.07%	30
2025 Q4	$1.08M	Buy	+23,300	New	+$1.04M	0.06%	36

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Progeny 3 Inc's PCVX Position: Q2 2026 in Review

Progeny 3 Inc sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 23,300 shares — an estimated $1.35M sold.

Progeny 3 Inc first reported a position in PCVX in Q4 2025 and held it in 2 quarters. The position peaked at $1.35M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Progeny 3 Inc reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Progeny 3 Inc sold 23,300 Vaxcyte shares in Q2 2026, an estimated $1.35M.
Progeny 3 Inc first reported a position in Vaxcyte in Q4 2025 and held it in 2 quarters.
Progeny 3 Inc's Vaxcyte position peaked at $1.35M in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Progeny 3 Inc's 13F filing for Q2 2026, filed 14 Aug 2026.